About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT05340218

Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment

Validate speech analysis AI models: * To contrast the accuracy of acceXible's platform as a screening tool in the detection of people with cognitive impairment and mild dementia. * To evaluate the co...

Lead sponsor: Accexible•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Accexible

Age

55 - 90 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Adult patients 55+ years of age with suspected MCI or diagnosis of dementia and obtains a score greater than 20 on the MMSE.
•Patients must have agreed to participate in the study and have voluntarily signed the informed consent.
•(Healthy) Participants without a diagnosis neurological, or psychiatric disorders. Or taking medication that can affect cognitive abilities.

Exclusion Criteria

•To have received a diagnosis of a significant psychiatric disorder or other cognitive impairment not due to neurodegeneration.
•To have significant vision problems that would affect the ability to perceive visual stimuli.
•To have significant hearing problems that would affect the ability to understand verbal cues.

Related studies

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

NCT06347315 · Mild Cognitive Impairment

rTMS Combined With Aerobic Exercise for Older Adults With Mild Cognitive Impairment and Comorbid Depression

NCT07652775 · Mild Cognitive Impairment (MCI), Depressive Symptoms

Clinical Procedures to Support Research in ALS

NCT03489278 · Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, and more

Resilient Together for Dementia (RT-D)

NCT06619327 · Dementia

RECRUITINGPhase 2

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

NCT07029581 · Lewy Body Dementia Psychosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 25, 2026Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment196

Start dateJan 2019

Last updatedMar 25, 2026

Condition

Mild Cognitive Impairment Dementia

Locations shown

Centro de Prevención de Deterioro Cognitivo

Madrid, Madrid

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 25, 2026Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions